Indian Journal of Cancer Home 

ORIGINAL ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2013  |  Volume : 50  |  Issue : 3  |  Page : 261--267

Clinico-pathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: Experience from India

PS Kadam Amare1, V Gadage2, H Jain1, S Nikalje1, S Manju3, N Mittal2, S Gujral2, R Nair3 
1 Cancer Cytogenetics Laboratory, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India
2 Hematopathology Laboratory, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India
3 Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India

Correspondence Address:
PS Kadam Amare
Cancer Cytogenetics Laboratory, Tata Memorial Hospital, Parel, Mumbai, Maharashtra
India

Background: The present study of 238 B-cell Chronic Lymphocytic Leukemia (B-CLL) patients were undertaken to seek the prevalence and to evaluate clinico-pathological significance of recurrent genetic abnormalities such as del(13q14.3), trisomy 12, del(11q22.3) (ATM), TP53 deletion, del(6q21) and IgH translocation/deletion. Materials and Methods: We applied interphase - fluorescence in situ hybridization (FISH) on total 238 cases of B-CLL. Results: Our study disclosed 69% of patients with genetic aberrations such as 13q deletion (63%), trisomy 12 (28%), 11q deletion (18%), 6q21 deletion (11%) with comparatively higher frequency of TP53 deletion (22%). Deletion 13q displayed as a most frequent sole abnormality. In group with coexistence of ≥2 aberrations, 13q deletion was a major clone indicating del(13q) as a primary event followed by 11q deletion, TP53 deletion, trisomy 12, 6q deletion as secondary progressive events. In comparison with del(13q), trisomy 12, group with coexistence of ≥2 aberrations associated with poor risk factors such as hyperleukocytosis, advanced stage, and multiple nodes involvement. In a separate study of 116 patients, analysis of IgH abnormalities revealed either partial deletion (24%) or translocation (5%) and were associated with del(13q), trisomy 12, TP53 and ATM deletion. Two of 7 cases had t(14;18), one case had t(8;14), and four cases had other variant IgH translocation t(?;14). Conclusion: Detail characterization and clinical impact are necessary to ensure that IgH translocation positive CLL is a distinct pathological entity. Our data suggests that CLL with various cytogenetic subsets, group with coexistence of ≥2 aberrations seems to be a complex cytogenetic subset, needs more attention to understand biological significance and to seek clinical impact for better management of disease.


How to cite this article:
Amare PK, Gadage V, Jain H, Nikalje S, Manju S, Mittal N, Gujral S, Nair R. Clinico-pathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: Experience from India.Indian J Cancer 2013;50:261-267


How to cite this URL:
Amare PK, Gadage V, Jain H, Nikalje S, Manju S, Mittal N, Gujral S, Nair R. Clinico-pathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: Experience from India. Indian J Cancer [serial online] 2013 [cited 2019 Oct 24 ];50:261-267
Available from: http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2013;volume=50;issue=3;spage=261;epage=267;aulast=Amare;type=0